CHRS (Coherus BioSciences) Net earnings per share growth this year

CHRS (Coherus Biosciences) - company brandmark

Coherus Biosciences (CHRS) is currently shifting its strategic direction, pivoting from biosimilars toward the development of its own immuno-oncology pipeline and cost optimization. A key advantage is its monopoly in treating rare carcinomas, despite pricing battles in other segments. However, logistical disruptions and sanctions are limiting expansion. The annual change in earnings per share reflects the pace of the business turnaround, where 43.10 expresses the current value of the metric.

Earnings per share growth in current year: Coherus (CHRS) for 07/04/2022 - 11/17/2026

Financial and market metric breakdowns for coherus.com (CHRS)

Summary company analysis:CHRS Coherus Biosciences
Signature product of Coherus Biosciences

Coherus Biosciences (CHRS) specializes in developing affordable biosimilars and introducing the innovative drug Loqtorzi into the oncology segment. By analyzing the EPS YoY percentage shift, an investor assesses the rate of change in net income per share relative to the previous year, which allows for determining the effectiveness of the business model's adaptation to the cost of borrowed capital and the company's overall profitability resilience.

Key competitors

Earnings per share growth this year INCY|Earnings per share growth in current year Hutchison MediPharma|Net earnings per share growth this year nuvationbio.com (NUVB)|Earnings per share growth in current year Day One Biopharmaceuticals Inc (DAWN)|MNPR - Earnings per share growth rate in current year|Earnings per share growth in current year Inhibrx Biosciences Inc INBX|I-Mab - Earnings per share growth in current year|FENC - Earnings per share growth in current year|Earnings per share growth rate in current year herontx.com|NVCT: Earnings growth in current year|Net earnings per share change in current year Corbus Pharma CRBP|Net earnings per share growth this year CRDF|Earnings per share growth rate in current year BeyondSpring Inc. BYSI|Net earnings per share growth this year BCAB (BioAtla Inc)|LIXT (Lixte Biotechnology Holdings, Inc.) - Earnings per share increase in current year|Citius Pharmaceuticals, Inc. - Net earnings per share growth this year|Net earnings per one share growth for the current year CLRB (Cellectar Biosciences, Inc.)|BioLineRx Corp - Earnings growth in current year|Earnings per share increase in current year CANF (Can-Fite BioPharma, Ltd.)|APRE: Earnings growth in current year|Earnings per share growth rate in current year Kazia (KZIA)|Earnings per share growth in current year silexion.com|NCNA: Earnings per share increase in current year|Earnings growth in current year CMRX|Earnings growth in current year Cyclacel, Inc. (CYCC)|Earnings per share growth in current year G1 Therapeutics Inc. GTHX|KRON (Kronos Bio) - Earnings per share trend in current year|KTRA: Net earnings per share growth this year|Earnings per share growth rate in current year Oncternal Therapeutics Inc|Portage Biotech (PRTG) - Earnings per share growth in current year